Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Mr McCann has Board experience with some of Australia's companies. He is a former corporate lawyer and Chairman and Director of listed private and government companies, and government agencies. Mr McCann's expertise in shaping culture (including through organisational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring insights in these areas. He previously served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Origin Energy Limited (from January 2000 to October 2013) and the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018). He was also previously a Director of Bluescope Steel Ltd (from May 2002 to April 2013) and E&P Financial Group Limited (from February 2020 to November 2021). He was also a Director of the U.S. Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). Currently, Mr McCann is a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Chairman of China Matters (since November 2018), a Director of Haydn Ensemble (since December 2020), and Chair and Board Advisor of Blueprint Institute (since June 2022). Mr McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020. He is member of risk committee and chair of People, Culture and Disclosure Committee.

Ms Skinner has financial acumen, accounting and auditing expertise, with an understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as an independent Non-Executive Director of QBE Insurance Group Limited (since October 2014) and a Director of Create Foundation Limited (since June 2004). She also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023). SHe is member of People, Culture Committee and Disclosure Committee and chair of Risk Committee.

Dr Behrenbruch has radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialisation. Dr Behrenbruch has a focus on purpose and values-leadership and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Committee.

Dr Nelson has experience in the investment community, including in life sciences. Dr Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of People, Culture and Risk Committee.

Ms Olson brings experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceuticals sector. Ms Olson's most recent executive role was with Cardinal Health, the largest provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network, she led a business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022) and a Partner at Trusted Health Advisors (since August 2023). She is member of Risk Committee.

-

-

-

-

-